ChristopherJohnKenneyMD

PubMed

• 2 citations
  Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, pr...
  Hubert H Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A Schwarzschild
  Parkinsonism & Related Disorders. 2023-09-01
• 19 citations
  Assessment of gait and balance impairment in people with spinocerebellar ataxia using wearable sensors.
  He Zhou, Hung Nguyen, Ana Enriquez, Louie Morsy, Michael Curtis
  Neurological Sciences. 2021-10-19
• 2 citations
  Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.
  C. Warren Olanow, Christopher Kenney, Stephen Bandak, Karl Kieburtz
  Movement Disorders. 2018-11-01

Journal Articles

• Safinamide as adjunct to levodopa in Parkinson's disease patients with motor fluctuations: A 24-week randomized, double-blind, placebo-controlled trial  
  Schapira A, Fox S, Hauser R, Jankovic J, Jost W, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R, JAMA Neurology, 1/1/2017
• Pharmacokinetics and Metabolism of [14C]-Tozadenant (SYN-115), a Novel A2a receptor antagonist ligand, in Healthy volunteers  
  Mancel V, Mathy FX, Boulanger P, English S, Croft M, Kenney C, Knott T, Stockis A Bani M, Xenobiotica, 1/1/2017
• Two randomized phase 2 studies of mavoglurant in Parkinson's patients with L-dopa-induced dyskinesias  
  Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A, Mov Disord, 1/1/2016
• Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease  
  Kumar R, Hauser R, Mostillo J, Dronamraju N, Graf A, Merschhemke M, Kenney C, Int J Neurosci, 1/1/2016
• Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study  
  Lenderking WR, Mannix S, Petrillo J, Kenney C, Landrian A, Schrag Anette-Eleonore, Qual Life Res, 1/1/2015
• Tozadenant in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial  
  Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S, Lancet Neurol, 1/1/2014
• Use of metabotropic glutamate 5 receptor antagonists for treatment of levodopa-induced dyskinesias  
  Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B, Parkinsonism Relat Disord, 1/1/2014
• AFQ056 in Parkinson patients with L-dopa-induced dyskinesia: 13-week randomized, dose-finding study  
  Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang A, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C, Mov Disord, 1/1/2013
• Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease  
  Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, McCombs A, Miller A, Zesiewicz TA, Neurology, 1/1/2012
• Design innovations and baseline findings in a longterm Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's...  
  NINDS NET-PD Investigators, Mov Disord, 1/1/2012
• Efficacy and tolerability of pregabalin in essential tremor: A randomized, double-blind, placebo-controlled, crossover trial  
  Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J, J Neurol Sci, 1/1/2009
• Relationship between various clinical outcome assessments in patients with blepharospasm  
  Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G, Mov Disord, 1/1/2009
• Metoclopramide: An increasingly recognized cause of tardive dyskinesia  
  Kenney C, Hunter C, Mejia N, Davidson A, Jankovic J, J Clin Pharmacol, 1/1/2008
• CSF multivariate profile distinguishes Alzheimer and Parkinson diseases  
  Zhang J, Sokal I, Peskind E, Quinn J, Jankovic J, Kenney C, Chung K, Millard S, Nutt J, Montine T, Am J Clin Pathol, 1/1/2008
• Bilateral Pedunculopontine Nuclei Stroke Presenting as Freezing of Gait  
  Kuo SH, Kenney C, Jankovic J, Mov Disord, 1/1/2008
• Levodopa Induced Dyskinesia  
  Kenney C, Diamond A, Applied Neurology, 1/1/2007
• Hyperhidrosis due to thalamic deep brain stimulation in a patient with essential tremor  
  Diamond A, Kenney C, Almaguer M, Jankovic J, J of Neurosurg, 1/1/2007
• Distinguishing psychogenic from essential tremor  
  Kenney C, Diamond A, Mejia N, Hunter C, Jankovic J, J Neurol Sci, 1/1/2007
• The role of pedunculopontine deep brain stimulation in Parkinson's disease  
  Kenney C, Fernandez H, Okun M, Expert Rev of Neurother, 1/1/2007
• Rotigotine transdermal patch in the treatment of Parkinson's disease and Restless Leg Syndrome  
  Kenney C, Jankovic J, Expert Opin on Pharmacother, 1/1/2007
• GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric co-morbidities  
  Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J, Neurology, 1/1/2007
• Tetrabenazine in the treatment of Tourette syndrome  
  Kenney C, Hunter C, Mejia, N, Jankovic J, J of Ped Neuro, 1/1/2007
• Short-term and long-term safety of deep brain stimulation for the treatment of movement disorders  
  Kenney C, Simpson R, Hunter C, Ondo W, Davidson A, Almaguer M, Jankovic J, J of Neurosurg, 1/1/2007
• Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders  
  Kenney C, Hunter C, Jankovic J, Mov Disord, 1/1/2007
• Autopsy-proven Huntington's disease with 29 trinucleotide repeats  
  Kenney C, Powell, S, Jankovic J, Mov Disord, 1/1/2007
• Join now to see all

Books/Book Chapters

• Therapeutic Clinical Practice and Science 
  Chapter: Botulinum neurotoxin treatment of cranial-cervical dystonia. 
  Page 92 - 101Kenney C, Jankovic JEditors: Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N.Saunders (Elsevier), Philadelphia, PA2009
• Encyclopedia of Neuroscience 
  Chapter: Cranial-cervical dystonia. 
  Page 255 - 258Kenney C, Jankovic JEditors: Squire LR.Elsevier, Academic Press, Oxford2009
• Therapeutics of Parkinson's Disease and Other Movement Disorders 
  Chapter: Surgical treatments of dystonia. 
  Page 241 - 250Kenney C, Jankovic JEditors: Hallett M, Poewe W.John Wiley & Sons, Ltd., Chichester, UK2008
• MedLink Neurology 
  Chapter: Tardive Dyskinesia. 
  Kenney CEditors: Gilman S.Medlink Corporation, San Diego2006
• MedLink Neurology 
  Chapter: Myoclonus. 
  Kenney CEditors: Gilman S.Medlink Corporation, San Diego2006
• Join now to see all

Abstracts/Posters

• Fox Insight: A Large-scale Web-enabled Parkinson's Disease Study.
  Chahine L, Caspell-Garcia C, McLaughlin L, Marras C, Standaert D, Ravina B, Kenney C, Chowdhury S, Sherer T, Kopil C, 69th Annual American Academy of Neurology Meeting, Boston, MA, 1/22/2017
• Adverse Event Reporting in Clinical Trials - Time for Change.
  Kenney C, Kieburtz K, Olanow CW, Bandak S, ASENT 19th Annual Meeting, Rockville, MD, 1/14/2017
• Tozadenant Phase 3 study (TOZ-PD) in Parkinson's disease patients with motor fluctuations: Baseline characteristics.
  Kieburtz K, Olanow CW, Krishnaswami J, Resburg C, Kerwood F, Kenney C, 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC, 1/4/2017
• Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson's Disease.
  Kostrub C, Kenney C, Riemer C, Prinssen E, Flohr A, and Moreau J, 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC, 1/4/2017
• Associating patient impression of improvement with efficacy endpoints in Parkinson's disease: A post-hoc analysis of a tozadenant study.
  Kenney C, Glass A, Olanow CW, 21st International Congress on Parkinson's Disease and Movement Disorders, Vancouver, BC, 1/4/2017
• SYN120, a dual 5-HT6/5-HT2A antagonist, for Parkinson's disease dementia (SYNAPSE): Study design and partial blinded data.
  Weintraub D, Macklin E, Cartaya A, Pothier L, Kenney C, 4th World Parkinson Congress, Portland, OR, 1/20/2016
• SYN120, a dual 5-HT6/5-HT2A antagonist, for Parkinson's disease dementia (SYNAPSE): Study design and partial blinded data.
  Weintraub D, Macklin E, Cartaya A, Pothier L, Kenney C, 30th Annual Parkinson Study Group Symposium, Portland, OR, 1/17/2016
• Regional differences in the results of a phase 2b study of tozadenant in Parkinson's disease patients with motor fluctuations.
  Kenney C, Kieburtz K, Olanow CW, and Bandak S, Mov Disord, 1/1/2016
• Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson's disease patients with motor fluctuations.
  Kenney C, Kieburtz K, Olanow CW, and Bandak S, Mov Disord, 1/1/2016
• Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of...
  Kerwood F, Kenney C, Kieburtz K, Olanow CW, Resburg C, Krishnaswami J and Bandak S, Mov Disord, 1/1/2016
• 13-week, double-blind, placebo-controlled, fixed-dose study of modified release AFQ056, an mGluR5 receptor antagonist, in Parkinson's disease patients with moderate-to...
  Trenkwalder C, Kulisevsky J, Poewe W, Shah A, Han G, Tran M, Kenney C, Graf A, Mov Disord, 18th International Congress on Parkinson's Disease and Movement Disorders, Stockholm, Sweden, 1/8/2014
• 12-week, double-blind, placebo-controlled, fixed-dose study of immediate release AFQ056, an mGluR5 receptor antagonist, in Parkinson's disease patients with moderate-t...
  Stocchi F, Balaguer E, Trenkwalder C, Shah A, Dronamraju N, Tran M, Kenney C, Graf A, Mov Disord, 18th International Congress on Parkinson's Disease and Movement Disorders, Stockholm, Sweden, 1/8/2014
• Single and multiple dose pharmacokinetics of a modified-release (MR) formulation of the mGluR5 antagonist mavoglurant (AFQ056) in healthy Japanese subjects.
  Honma W, Yokoi A, Ufer M, Desai J, Kenney C, Woessner R, Mov Disord, 17th International Congress on Parkinson's Disease and Movement Disorders, Sydney, Australia, 1/16/2013
• A 6-week, double-blind, multicenter RCT in Parkinson's disease patients to explore the efficacy and safety of AFQ056 when combined with increased doses of L-dopa.
  Kumar R, Hauser R, Mostillo J, Dronamraju N, Graf A, Kenney C, Merschhemke M, Mov Disord, 16th International Congress on Parkinson's Disease and Movement Disorders, Dublin, Ireland, 1/17/2012
• Lubiprostone for constipation in Parkinson's disease, a multicenter, placebo controlled parallel trial.
  Ondo WG, Kenney C, Daleiden A, Davidson A, Hunter C, Jahan I, Miller A, Sullivan K, Zesiewicz TA, Mov Disord, 15th International Congress of Parkinson's Disease and Movement Disorders, Toronto, Canada, 1/5/2011
• SETTLE study design: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinso...
  Schapira A, Fox S, Hauser R, Jankovic J, Kulisevsky J, Pahwa R, Poewe W, von Raison F, Kenney C, Musch B, Eur J Neurol, 14th European Federation of Neurological Sciences, Geneva, Switzerland, 1/25/2010
• MOTION (safinamide add-on to dopamine agonist in early idiopathic Parkinson's disease) study design: a 24-week, double-blind, placebo-controlled study of the efficacy ...
  Barone P, Fernandez H, Ferreira J, Muller T, Saint-Hilaire M, Stacy M, Tolosa E, von Raison F, Kenney C, Musch B, Eur J Neurol, 14th European Federation of Neurological Sciences, Geneva, Switzerland, 1/25/2010
• MOTION (safinamide add-on to dopamine agonist in early idiopathic Parkinson's disease) study design: a 24-week, double-blind, placebo-controlled study of the efficacy ...
  Barone P, Fernandez H, Ferreira J, Müller T, Saint-Hilaire M, Stacy M, Tolosa E, von Raison F, Kenney C, Musch B, Mov Disord, 14th International Congress of Parkinson's Disease and Movement Disorders, Buenos Aires, Argentina, 1/13/2010
• SETTLE study design: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinso...
  Schapira A, Fox S, Hauser R, Jankovic J, Kulisevsky J, Pahwa R, Poewe W, von Raison F, Kenney C, Musch B, Mov Disord, 14th International Congress of Parkinson's Disease and Movement Disorders, Buenos Aires, Argentina, 1/13/2010
• A 17-Week, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Trial of Pregabalin (PGB) in Essential Tremor (ET).
  Ferrara J, Kenney C, Shinawi L, Kissel A, Jankovic J, 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, 1/7/2009
• Autopsy-proven Huntington disease with 29 trinucleotide repeats.
  Kenney C, Powell S, Jankovic J, Neurology, 59th Annual American Academy of Neurology Meeting, Boston, MA, 1/28/2007
• Motor and behavioral outcomes after bilateral GPi deep brain stimulation for severe Tourette syndrome.
  Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J, Mov Disord, 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey, 1/3/2007
• Deep brain stimulation for tardive dyskinesia and akathisia.
  Kenney C, Barbano R, Sheffield J, Jankovic J, Mov Disord, 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey, 1/3/2007
• Health related quality of life in essential tremor patients undergoing deep brain stimulation.
  Kenney C, Diamond A, Shinawi L, Jankovic J, Mov Disord, 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey, 1/3/2007
• Health related quality of life in Parkinson disease patients undergoing deep brain stimulation.
  Kenney C, Diamond A, Shinawi L, Jankovic J, Mov Disord, 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul, Turkey, 1/3/2007
• Join now to see all